Aspirin use for primary prophylaxis: Adverse outcomes in non-variceal upper gastrointestinal bleeding

Table 1 Clinical characteristics of patients with non-variceal upper gastrointestinal bleeding in both groups n (%)

Group	No anti-thrombotics n = 263	Aspirin n = 94	P value
Age mean (SD)	58.4 (19.1)	66.8 (13.1)	< 0.001
Male gender	169 (64.3)	71 (75.5)	0.05
Smoking	60 (27.0)	34 (41.0)	0.02
Diabetes mellitus	31 (11.8)	25 (26.6)	0.001
Hypertension	74 (28.1)	44 (46.8)	0.001
Dyslipidemia	16 (6.1)	21 (22.3)	< 0.0001
Cancer	55 (20.9)	6 (6.4)	0.001
NSAIDS	47 (17.9)	16 (17.0)	0.85
PPI	29 (11.0)	4 (4.3)	0.05
History of peptic ulcer disease	69 (26.2)	13 (13.8)	0.01

P < 0.05 is considered significant. NVUGIB: Non-variceal upper gastrointestinal bleeding; Aspirin: Aspirin only; No anti-thrombotics: Including clopidogrel, coumadin, heparin, ticlopedine and dypiradamole; SD: Standard deviation; NSAIDS: Non steroidal anti-inflammatory drug; PPI: Proton pump inhibitor.